Allogene Therapeutics, Inc. (NASDAQ:ALLO) to Post FY2022 Earnings of ($2.43) Per Share, Oppenheimer Forecasts

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) – Equities researchers at Oppenheimer increased their FY2022 earnings per share estimates for shares of Allogene Therapeutics in a report released on Tuesday, August 9th. Oppenheimer analyst M. Breidenbach now expects that the company will earn ($2.43) per share for the year, up from their previous forecast of […]

Related Keywords

Raymond James ,Owenn Witte ,Rafael Amado ,Robertw Baird ,Primecap Management Co ,Securities Exchange Commission ,Allogene Therapeutics Inc ,Goldman Sachs Group Inc ,Blackrock Inc ,Nasdaq ,Jpmorgan Chase Co ,Goldman Sachs Group ,Allogene Therapeutics ,Get Rating ,Allogene Therapeutic ,Exchange Commission ,Director Owen ,Street Corp ,Sachs Group ,Nasdaq Allo ,Allo ,Medical ,Earnings Estimates ,Oppenheimer Holdings Inc ,